Praxis precision medicines announces rare pediatric disease designation granted for relutrigine in dravet syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (dee) often caused by a mutation in scn1a this is the third rare pediatric disease designation for relutrigine, adding to those granted for scn2a and scn8a dees praxis plans to initiate an all-dee trial (emerald), inclusive of dravet syndrome, in 1h2025 boston, dec. 18, 2024 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced the u.s. food and drug administration (fda) has granted rare pediatric disease designation (rpdd) for relutrigine in dravet syndrome. “we are thrilled to have been granted rare pediatric disease designation for relutrigine in dravet syndrome.
PRAX Ratings Summary
PRAX Quant Ranking